Dipeptidyl peptidase-4 inhibitor improves glycemic variability in multiple daily insulin-treated type 2 diabetes: a prospective randomized-controlled trial

Aims To improve glycemic variability (GV) is crucial in the management of multiple daily insulin (MDI) treatment in diabetes. To evaluate the GV improvement in MDI treated type 2 diabetes (T2D) with low-dose metformin 750 mg/day (LMET), which was popular in the clinical practice in Japan, we compare...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetology International 2022-01, Vol.13 (1), p.124-131
Hauptverfasser:	Yoshikawa, Fukumi, Uchino, Hiroshi, Nagashima, Tomoko, Usui, Shuki, Miyagi, Masahiko, Ando, Yasuyo, Hirose, Takahisa
Format:	Artikel
Sprache:	eng
Schlagworte:	Antidiabetics Blood glucose Blood sugar Blood sugar monitoring Body weight Clinical trials Comparative analysis Diabetes Diabetes mellitus (non-insulin dependent) Diabetes therapy Dipeptidyl-peptidase IV Endocrinology Glucose monitoring Glycosylated hemoglobin Hyperglycemia Hypoglycemia Insulin Medical colleges Medicine Medicine & Public Health Metabolic Diseases Metformin Original Original Article Peptidase Type 2 diabetes
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Aims To improve glycemic variability (GV) is crucial in the management of multiple daily insulin (MDI) treatment in diabetes. To evaluate the GV improvement in MDI treated type 2 diabetes (T2D) with low-dose metformin 750 mg/day (LMET), which was popular in the clinical practice in Japan, we compared the effect of adding vildagliptin 100 mg/day (LMET + DPP4i treatment) or increased metformin dose to 1500 mg/day (HMET treatment), in the setting of continuous glucose monitoring (CGM) analysis. Materials and methods Single-center, open-label, 12 weeks—two period cross-over design. Twenty T2D with inadequately controlled (7.0%
ISSN:	2190-1678 2190-1686
DOI:	10.1007/s13340-021-00513-6